title: Rosiglitazone, PPARγ, and type 2 diabetes.
authors.affiliation: Division of Endocrinology, Diabetes, and Metabolism, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, USA.
authors.forename: Barbara B
authors.initials: BB
authors.lastname: Kahn
authors.forename: Timothy E
authors.initials: TE
authors.lastname: McGraw
mesh_terms: D051360:Cyclin-Dependent Kinase 5 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000517:prevention & control*; D015870:Gene Expression; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D009765:Obesity / Q000378:metabolism; D047495:PPAR gamma / Q000378:metabolism*; D010766:Phosphorylation / Q000187:drug effects; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D007004:Hypoglycemic Agents; D047495:PPAR gamma; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D051360:Cyclin-Dependent Kinase 5